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Stiffness is more than just duration and severity:
a qualitative exploration in people with rheumatoid
arthritis
Serena Halls1, Emma Dures1, John Kirwan2, Jon Pollock1, Gill Baker3,
Avis Edmunds3 and Sarah Hewlett1
Abstract
Objective. Stiffness is internationally recognized as an important indicator of inflammatory activity in RA
but is poorly understood and difficult to measure. The aim of this study was to explore the experience
of stiffness from the patient perspective.
Methods. Semi-structured interviews conducted with 16 RA patients were analysed independently by
researchers and pat.ient partners using inductive thematic analysis.
Results. Six themes were identified. Part of having RA identified stiffness as a normal consequence of RA,
perceived as associated with disease-related aspects such as fluctuating disease activity, other RA symp-
toms and disease duration. Local and widespread highlighted stiffness occurring not only in joints, but
also over the whole body, being more widespread during the morning or flare. Linked to behaviour and
environment illustrated factors that influence stiffness, including movement, medications and weather.
Highly variable captured the fluctuating nature of stiffness within and between patients and in relation
to temporality, duration and intensity. Impacts on daily life emphasized the effect of stiffness on a range
of domains, including physical function, quality of life, psychological well-being, activities of daily living
and participation in work and leisure activities. Requires self-management detailed self-management
strategies targeting both the symptom and its consequences.
Conclusion. Patients’ experiences of stiffness were varied, complex and not exclusive to the morning
period. Importantly, stiffness was reported in terms of impact rather than the traditional measurement
concepts of severity or duration. Based on these findings, further research is needed to develop a patient-
centred measure that adequately reflects inflammatory activity.
Key words: stiffness, rheumatoid arthritis, patient experience, qualitative.
Introduction
RA is a chronic, systemic, inflammatory condition causing
synovitis and resulting in pain, swelling and stiffness [1].
Morning stiffness (MS) is included in the original ACR clas-
sification of RA and remission criteria [2, 3]. Early MS
(EMS) is considered an indicator of inflammatory activity
and rheumatologists use stiffness as a crucial variable in
decision-making for changing medication [4, 5]. MS is also
widely used in RA research, particularly pharmacological
trials [6], and is a key outcome in current research into
timed-release glucocorticoid treatments [7, 8]. Stiffness
in the inflammatory process is thought to be related
to increases in pro-inflammatory cytokines such as IL-6
[9, 10].
Clinically, stiffness is frequently reported by patients
[11, 12] and has considerable effects on daily life, work
and quality of life [1315]. However, these studies have
generally focused on morning function, making it difficult
to differentiate stiffness from pain and disability. In quali-
tative research by the OMERACT Flare Working Group,
patients considered MS to be an important influence on
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decisions to seek medication review [16]. In the resultant
combined international patient and professional Delphi
exercise, stiffness was prioritized as a potential item for
a core set of flare measures (79% consensus) [17].
Furthermore, in a recent qualitative study, patients high-
lighted stiffness reduction as a crucial aspect of RA
remission [18].
Traditionally, assessment is through questions about
EMS duration or severity. However, different question for-
mats [visual analogue scales (VASs), numerical rating
scales, Likert scales] for severity are not interchangeable
and severity does not correlate with duration [19]. Patients
who answer no to the presence of EMS have later re-
ported its duration in minutes in a subsequent question,
implying the questions are unclear [12]. Given these
measurement difficulties, it is vital to understand the con-
cept of stiffness from the patient perspective if we are to
evaluate it effectively. Only one study has focussed on
understanding the patient experience of stiffness [20],
but it was conducted more than a decade ago, since
when there have been substantial changes in RA treat-
ment [21] and thus likely changes in stiffness experience.
Furthermore, no validated stiffness measure has been
developed using the recommended methodology includ-
ing concept mapping through qualitative exploration [22].
Therefore the aim of this study was to explore the experi-
ences of stiffness in patients with RA.
Patients and methods
Following ethics approval (Leeds East Research Ethics
Committee, 13/YH00/50) patients with confirmed RA [2]
and experience of RA-related stiffness were invited to par-
ticipate in semi-structured interviews. Patients attending
outpatient clinics at two National Health Service (NHS)
trusts were purposefully sampled using a sampling
frame to reflect a range of age, gender and disease
duration.
An interview guide (Table 1) was developed based on a
literature review and discussion with the research team
(Table 2). Interviews and analysis followed an iterative
process that allowed ideas and concepts identified in
early analysis to be explored in subsequent interviews
[23]. All patients gave informed consent and completed
a disability questionnaire (HAQ) [24], perceived disease
activity VAS [25] and pain VAS. All interviews were con-
ducted by one researcher (S. Halls) who was unknown to
participants prior to the study and introduced herself as a
non-clinical researcher. Interviews were conducted with
only the researcher and participant present except for
one interview where the participant brought her young
son. Interviews took place in non-clinical rooms, lasted
between 30 and 80 min, were audio-recorded and then
transcribed verbatim. Data collection continued until
saturation was reached and no new themes were
emerging.
Data were analysed using inductive thematic ana-
lysis, a method of identifying and reporting patterns
in data without the use of an a priori model [26]. Data
were managed using NVivo 10 (QSR International,
Doncaster, VC, Australia) [27] and Microsoft Office
Word 2007. Transcripts were read, re-read and system-
atically coded, then codes were explored for patterns,
which led to theme development [26]. The interviewer
(S. Halls) analysed all transcripts. Researchers
(S. Hewlett, E.D.) independently analysed two tran-
scripts, patient research partners [28] (G.B., A.E.), after
a brief introduction, also read two transcripts and
highlighted relevant points from their perspective, and
discussions among the research team throughout the
analysis process facilitated agreement on the developing
codes and themes.
Results
Sixteen of 38 patients who were approached agreed to
participate (42%): 11 female, aged 3378 years, disease
duration 127 years (Table 3). Analysis identified 219
TABLE 1 Interview guide
A. Can you tell me about your experience of stiffness in
relation to RA?
B. How does this vary in a 24 h period?
C. Has stiffness varied over the course of your disease?
D. How does stiffness differ from other RA symptoms?
E. What are the consequences of stiffness?
F. How do you deal with stiffness?
G. How do you assess stiffness?
H. Is there anything that you feel is important to stiffness
that we have not talked about?
TABLE 2 Study team characteristics
Team Gender Position Years of rheumatology experience
S. Halls F PhD researcher 2 years
E.D. F Rheumatology psychology researcher 5 years
J.K. M Academic rheumatologist >30 years
J.P. M Epidemiologist >10 years
G.B. F Patient research partner RA diagnosed 510 years
A.E. F Patient research partner RA diagnosed 410 years
S. Hewlett F Academic rheumatology nurse >20 years
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codes that were grouped into six themes (see
Supplementary Table S1, available at Rheumatology
Online) that captured the patients’ experiences of RA stiff-
ness (Fig. 1).
Theme 1: part of having RA
Patients considered stiffness to be part of their disease
and a normal consequence of RA: ‘All rheumatoid arthritis
sufferers get used to a level of pain and a level of
TABLE 3 Individual participant demographic data
Patient
ID Gender
Age,
years
Disease
duration,
years HAQ PtG Pain Current medication
101 Male 62 22 1.25 1.3 9.0 NSAIDs, DMARDs, glucocorticoids, biologics
102 Female 48 25 2.25 3.9 5.4 NSAIDs, DMARDs, biologics
103 Male 71 11 1.50 3.7 2.2 NSAIDs, glucocorticoids
104 Male 78 1 0.25 4.7 0.0 DMARDs glucocorticoids
105 Female 62 15 1.63 y y DMARDs, glucocorticoids, biologics
106 Female 62 2 1.13 y y DMARDs, glucocorticoids
107 Female 37 9 1.50 3.5 3.6 NSAIDs, glucocorticoids, biologics
108 Female 60 2 2.25 10.0 10.0 DMARDs
109 Female 33 3 2.13 1.6 5.8 NSAIDs, DMARDs, biologics
110 Female 63 7 2.50 4.9 4.9 NSAIDs, DMARDs
111 Male 74 7 1.50 1.8 5.2 DMARDs
112 Female 48 23 2.63 4.6 7.6 NSAIDs, DMARDs
113 Female 48 14 1.00 3.2 3.7 NSAIDs
114 Female 71 14 1.75 y y NSAIDs, DMARDs
115 Male 45 2 1.88 2.8 6.7 DMARDs, biologics
116 Female 55 27 1.00 6.5 7.7 DMARDs
Mean — 57.3 11.5 1.63 4.0 5.5 —
S.D. — 13.2 8.9 0.63 2.3 2.8 —
Range — 3378 127 0.252.63 1.310.0 0.010.0 —
HAQ: 03 (3 = severe disability); PtG: patient perceived global disease activity, 010 VAS (10 = severe disease); pain: 010;
VAS: visual analogue scale, 010 (10 = severe pain); y: incomplete data.
FIG. 1 Conceptual diagram of the patient experience of stiffness
www.rheumatology.oxfordjournals.org 617
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stiffness which they consider to be normal’ (Patient 101).
RA stiffness was considered different from stiffness
as a result of exercise, due to differences in location,
occurrence and experience:
For me, muscle stiffness used to be, because obvi-
ously it’s associated with working out [. . .] it was like
a nice ooh God yeah, I’m really stiff today [. . .] but
with arthritis you know it’s an on-going [. . .] so it’s
a negative stiffness. Because you, after a while, you
don’t realise this at the time, but it won’t go away.
(Patient 112)
Patients felt that stiffness varied with fluctuations in
disease activity: ‘it’s much worse on a flare-up’ (Patient
113). Patients who also had stiffness from joint damage
indicated that stiffness from mechanical and inflammatory
processes felt different in terms of severity and
persistence:
I suppose a joint that’s gone over, it’s knackered, is a
restrictive stiffness and pain but a joint that’s flared is
a completely different feeling [. . .] once you’ve got
damage, you’re always stiff. (Patient 112)
Relationships with other RA symptoms were apparent,
most significantly between pain and stiffness, which was
stronger during flares:
I think they are separate but when, you know, when
everything’s sore, everything’s swollen and every-
thing’s stiff, it’s all kind of you know, in a bag
together and then you’re just in a pickle really.
(Patient 109)
Although some found it difficult to differentiate, most
patients could discuss pain and stiffness independently
and felt they were different yet related concepts:
‘They’re connected and related but they’re not interde-
pendent [. . .] if I’ve got stiffness it’s not guaranteed I’ve
got pain’ (Patient 107).
For some patients, stiffness was particularly significant
in early disease: ‘My rheumatoid arthritis started just
after [my son] was born [. . .] and it started with morning
stiffness’ (Patient 109). For others it appeared to be more
prominent later in their disease duration: ‘I used to have
the morning stiffness only really. It’s only really in the
last few years that I’ve started getting evening stiffness
as well’ (Patient 107).
Theme 2: local and widespread
Patients considered stiffness to relate to joints: ‘. . . in the
joint [. . .] and right deep in the joint’ (Patient 110). Some
patients highlighted that certain joints were affected, while
others suggested the location varied over the course
of their disease:
It is a bit random, it does tend to move around,
I might be sort of 6 months with it really bad in
my feet and my knees and then I might find that
it is worse in my back and hips and then it might
move up to my shoulders and my elbows.
(Patient 102)
For some patients, stiffness was described as being
more of a whole-body experience, particularly during the
morning or flare: ‘. . . stiffness when you’re getting up, it
feels like all up your arms and your legs and your whole
body more’ (Patient 116).
Theme 3: Linked to behaviour and environment
While patients related stiffness to their disease, they also
associated it with their behaviour and environment.
Stiffness was considered a result of both immobility: ‘Oh
it’s always much more difficult to get up after sitting still’
(Patient 103) and overactivity: ‘. . . if I have had a busy day,
and I haven’t been able to rest [. . .] then I might find that
it is creeping back in the evening as well’ (Patient 102).
Medications were perceived to influence the duration,
severity and impact of stiffness: ‘. . . this morning it was
about half an hour [. . .] and that’s with taking the steroids,
which does make it easier’ (Patient 113) and
I have been on the (Drug name A) now for just
coming up to 3 months [. . .] I feel better but I still
suffer with the stiffness, especially in the mornings.
Whereas on the (Drug name B) I never suffered any
of that, I just woke up in the morning and it was just
like I was normal. (Patient 115)
Patients sometimes felt that the dramatic effect of
medication on stiffness was ignored due to the lack
of an appropriate assessment method:
I kind of feel that it’s sort of a lost entity because
actually the drug is working, one of the things that
they’ve really transformed has been my stiffness,
but it’s never been a measure that’s kind of been
considered [. . .] the one thing they’ve never asked
me about is joint stiffness and the one thing I’m ab-
solutely delighted about is that I can now get up and
get him [my son] up whereas I haven’t for two and a
half years because I can’t do that in the morning [. . .]
and like the nurses all know and that’s great but if
they measured it they’d be brilliant because I could
then say ‘Yeah, look’, you know? (Patient 109)
Some patients also suggested that cold and wet con-
ditions accentuated stiffness duration, severity and
impact: ‘I suspect that today what with it being cold and
so on, I’ll probably continue to feel much as I do right
now until possibly eight or nine at night’ (Patient 103)
and ‘. . . I do like the sunshine [. . .] I just feel not so stiff
everywhere [. . .], whereas when it’s tipping in rain I’m so
blooming stiff I’ve got a job to move’ (Patient 105).
Theme 4: highly variable
Patients emphasized the highly variable nature of stiff-
ness, which varied in time, duration and intensity, within
and between patients:
. . . if you are an active person again your level of stiff-
ness [. . .] would be different for somebody who sat
down watching the television, or doing nothing or
reading a book or whatever. They are going to get
a lot more stiff than an active person. (Patient 101)
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and
. . . sometimes its only 10 minutes and I can get
rid of it really quite quickly and then other times
it is just hanging on and I just gradually just
shed it through the first hour or so of the day.
(Patient 102)
Although patients did relate stiffness to the morning
period: ‘. . . stiffness, it’s always there in the mornings,
sometimes it’s very bad’ (Patient 103), the majority high-
lighted a broader, variable temporal pattern. They
reported stiffness as lasting all day: ‘. . . the stiffness is
there give or take 24/7. It comes and goes in waves as
it were, but at the same time, it never really goes away’
(Patient 110), or recurring in the evenings: ‘. . . I have
the usual stiffer in the morning and stiffer at the end of
the day’ (Patient 107).
During flares, stiffness was described as ‘an exagger-
ation of itself’ (Patient 109). It was perceived to increase
in duration:
. . . [stiffness] will vary anything from about half
an hour to, I have had up to about two/three
hours, unless I’ve obviously had a bit of a flare
up, then obviously it can be all day thereabouts.
(Patient 107)
It was perceived as more severe:
I can tell if I am going through a period when not
being controlled very well cause the activity will
increase [. . .] I am stiffer either first thing in the morn-
ing or getting towards tea time in the evening.
(Patient 102)
It also had greater impact:
Just everything I think when you get a flare and it’s
really bad. Again it’s just your hands just don’t work
basically. They can’t bend them, grip things, and
obviously it’s really painful and it makes everything
awkward. When they are not so bad you can do
basic stuff, you can pick up a kettle, you can do
bits and bobs. There is a big difference between
the two. (Patient 115)
Stiffness was also perceived to recur more frequently,
including at night, and affect more joints: ‘. . . it’s not just
on a morning it’s all throughout the night . . .’ (Patient 113).
Theme 5: impacts on daily life
Patients evaluated their stiffness in terms of its impact
rather than duration and severity. Physical function was
considerably influenced by stiffness, including reduced
mobility, balance, dexterity, grip and range and speed of
movement: ‘Just, I mean a job to move really, your limbs
and your joints, your fingers. You can move them but they
just, I just find it sometimes initially quite hard to do . . .’
(Patient 106) and
I mean it’s like the other day I lost a screw out of my
glasses and I could see this screw and it was down
there, and do you think I could get my fingers to pick
it up, I could not, I could not get my fingers to pick up
this blooming stupid screw. (Patient 105)
Stiffness was highlighted as impacting on quality of life,
and disruption of normality was stressed, as was impact
on ability to work: ‘I am not safe enough to be on a build-
ing site I don’t think, I couldn’t get up steps and stuff,
things that I used to do’ (Patient 102). Some patients
experienced an improved ability to cope with stiffness
as a result of retirement:
. . . getting up to go to work was getting worse
because it was taking longer to be able to get to
move to be able to put the car in gear [. . .] but,
I think now because I’m not working it’s easier,
I can cope with it better. (Patient 113)
Essential daily activities such as eating and dressing
were highlighted as being particularly affected by
stiffness:
I’d end up eating a lot of soup because I just can’t
get my mouth open as wide to take even just a
simple fork of food, and chewing just becomes
a total non-starter. Yeah so I get joint pain in my
jaw but also it’s really stiff. (Patient 109)
and ‘. . . it’s just when you’re stiff you just find it hard to do,
just to do stuff, whether it’s something really simple, it just
makes it so much more difficult basically’ (Patient 115).
Participation in leisure activities and hobbies were
restricted by stiffness:
I’m making my step-daughter her prom jewellery
at the moment and I can only do, whereas before
I would’ve just made it in a night no problem at all
but when I’m stiff [. . .] I can’t do it because I can’t
pick up the bead or pick up the needle. (Patient 109)
Many patients described frustration as a result of the
restrictions imposed by stiffness:
. . . I can find it quite frustrating at times, especially
when I really want to get something done by a cer-
tain time or by a certain day of the week, or because
I’ve got something else happening I need to get that
done. (Patient 107)
Patients also discussed how pain would result from
carrying out movements restricted by stiffness:
It’s difficult one to inflict, no matter how, you must
keep your range of movement, it’s difficult when
you are in pain to continuously move a joint into
that position where it hurts. But then if you don’t it
gets stiffer. (Patient 102)
Theme 6: requires self-management
Patients articulated numerous strategies to self-manage
stiffness and its consequences. Strategies targeted a
range of domains and were both direct (targeting stiffness)
and indirect (targeting the consequences of stiffness).
Direct movement-based strategies included moving,
stretching, moving while still in bed, and supporting or
www.rheumatology.oxfordjournals.org 619
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manipulating joints. For example, ‘. . . before I get up out of
bed I try to move all my joints just you know, while I am not
actually standing up to actually just try and get everything
moving a bit’ (Patient 102) and ‘Sometimes like this morn-
ing I had to physically bend my hands to get them to work
because they just won’t, they’re kind of just locked’
(Patient 115). Heat and cold techniques such as the use
of hot showers and ice packs were employed by many
patients to directly relieve stiffness: ‘Whereas stiffness
you can generally, you know like using hot and cold [. . .]
you can work it out’ (Patient 102) and ‘First thing in the
morning [. . .] hot water is wonderful. I can move then’
(Patient 105).
Indirect strategies to manage impact included behav-
iour adjustment:
People say ‘oh that’s a nice dress’ and I think yeah
it’s because I couldn’t get my jeans on but you know,
thanks though [. . .] and you just do it, you don’t really
think it I suppose. You just adapt in the morning.
(Patient 109)
Patients also described having to prepare and plan
tasks, including getting going earlier to compensate for
slower movements:
I had to go for an MRI scan before Christmas [. . .]
and that was about 10 o’clock in the morning, but it
was the only one that they had and I thought well,
I’ve just got to do it haven’t I? I’ve just got to move
myself a lot earlier. (Patient 105)
Patients also suggested that stiffness in a flare does not
reduce with usual self-management techniques: ‘So if I
have a hot shower on a standard day I’m up and going
[. . .] whereas on a bad day I can’t get it to reduce as well, it
just lasts and I can’t shift it’ (Patient 109).
For one, the only effective management was a steroid
injection: ‘So that’s extreme stiffness, and I am not exag-
gerating that [. . .] it seems the only way to resolve that one
is to have a massive injection of steroid’ (Patient 101).
Discussion
Patients experience stiffness as significant, variable and
complex. Stiffness was reported to be a normal part of
having RA, experienced in joints and more widespread,
related to behavioural and environmental factors and to
have marked variability (including not being limited to early
morning). It resulted in wide-ranging consequences that
had a major impact on patient’s daily lives and necessi-
tated self-management.
Patients placed greater importance on stiffness impact
than stiffness severity or duration. While impact was men-
tioned in earlier research [20], patient-reported outcome
measures (PROMs) have continued to rely on non-
standardized, unvalidated duration and severity ques-
tions. Although stiffness duration is most frequently
assessed in trials [12], stiffness severity has been reported
to have stronger correlations with relevant outcomes and
inflammatory markers [29]. Severity and duration do not
correlate [19] and a recent review of stiffness in low-
disease states [30] shows the only two PROM validation
studies make conflicting recommendations on whether
severity or duration is best [29, 31]. It is therefore time
to consider the potential effectiveness of measuring stiff-
ness via concepts beyond severity and duration. The most
compelling argument is for the impact of stiffness,
which was how patients in this study defined and evalu-
ated stiffness. This would fit with the impact triad, which
recommends considering not only the severity of an out-
come, but also its importance to patients and their ability
to self-manage it [32].
These patient perspectives on stiffness might explain
the poor performance of traditional stiffness questions.
Duration questions generally ask about EMS using various
baselines, including from awakening or from getting up,
and various endpoints, including start of improvement,
substantial improvement or complete resolution [31].
Importantly, patients in this study did not relate stiffness
exclusively to early morning, which could explain their
difficulty in trying to determine a start or end point.
In addition, traditional simple questions assume (but do
not specify) that patients evaluate stiffness related to
inflammatory processes, yet patients in this study could
identify differences in inflammatory and mechanical stiff-
ness. Finally, in existing assessment there is no consider-
ation of stiffness location, yet patients report stiffness
in single and multiple joints, as well as widespread
(non-joint) stiffness, which they consider more severe. In
moving forward to the development of individual items for
inclusion in an appropriate RA stiffness PROM, aspects
such as these should be captured to enhance the clarity
of the target concept [33, 34].
While this study included only 16 participants from two
NHS trusts in the same city, the sample included a range
of ages, gender, treatment regimens and disease dur-
ations. There may be cross-cultural differences in the per-
ception of stiffness, which is an area for further research.
Furthermore, data saturation was achieved [35]. A key
strength of the study included the reliability of the findings
through independent analysis by other members of the
research team [36].
These data provide important information about a well-
recognized symptom that has a major impact on patients’
daily lives and that is used internationally both clinically
and in research. Stiffness measurement to date is not
standardized, is unvalidated, inconsistent and unreliable
and has not been developed according to current stand-
ards including collaboration with patients [33, 34, 37]. The
importance of collaboration was demonstrated in fatigue,
where collaboration led to international consensus that it
should be assessed in addition to the core set in RA trials
and development of the Bristol RA Fatigue scales [3841].
This current study has demonstrated the importance of
stiffness to patients, including one patient who reported
that the significant impact of her medications went unrec-
ognized due to lack of an appropriate stiffness measure.
Further research now needs to use these data to develop
potential items for a stiffness PROM. Development and
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validation of a stiffness PROM will open up the potential
for stiffness to be included in the ACR disease activity
core set (currently omitted because it cannot be measured
with sensitivity or specificity) [42]. It would also address
the OMERACT 2010 research agenda item for develop-
ment of a stiffness PROM in relation to flare [43].
Rheumatology key messages
. For patients with RA who experience it, stiffness is
an important and complex symptom.
. Patients with RA generally characterize and define
stiffness by its impact rather than duration or
severity.
. These data have implications for the development
of an appropriate RA stiffness patient-reported
outcome measure.
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